genebas
deliveri
recombin
antibodi
gene
promis
therapeut
strategi
offer
numer
advantag
includ
sustain
antibodi
level
better
safeti
profil
lower
product
cost
describ
gener
recombin
antibodi
compris
fusion
protein
human
fc
singlechain
fv
deriv
hybridoma
secret
mab
neutral
west
nile
viru
wnv
shown
retain
parent
mab
specif
wnvneutral
capac
adenovirusmedi
vivo
deliveri
antibodi
gene
result
sustain
serum
level
lead
abrog
lethal
wnv
infect
anim
model
west
nile
flaviviru
introduc
western
hemispher
consid
import
emerg
pathogen
develop
vaccin
control
wnv
flaviviru
infect
continu
attract
consider
attent
pugachev
et
al
even
effici
flaviviru
vaccin
would
provid
littl
help
treatment
ongo
infect
transfer
specif
antibodi
ab
immunoglobulin
shown
abort
modifi
number
flaviviru
infect
phillpott
et
al
roehrig
et
al
schlesing
et
al
passiv
immun
ab
wnv
prevent
diseas
anim
infect
wnv
bennathan
et
al
diamond
et
al
engl
diamond
therapeut
use
human
immun
globulin
obtain
pool
donor
sera
collect
region
high
occurr
wnv
infect
suggest
bennathan
et
al
therapi
yet
wide
avail
genet
engin
provid
mean
gener
recombin
antibodi
recab
vitro
employ
eukaryot
express
system
thu
expand
therapeut
ab
repertoir
solubl
recab
demonstr
bind
effect
neutral
variou
viral
pathogen
vitro
vivo
prosniak
et
al
wu
et
al
effect
protect
wnv
achiev
passiv
transfer
wnv
specif
recab
gould
et
al
oliph
et
al
throsbi
et
al
howev
product
clinic
grade
antibodi
passiv
immun
either
natur
engin
complic
due
highqual
standard
appli
clinic
grade
ab
prepar
cost
ab
product
andor
purif
extrem
high
kasuya
et
al
attract
altern
passiv
inocul
protect
antibodi
vivo
product
therapeut
ab
gene
transfer
variou
deliveri
vector
nonvir
viral
develop
genet
transfer
antibodi
gene
bakker
et
al
although
adenoviru
ad
gene
transfer
vector
use
deliv
recab
cancer
applic
alvarez
et
al
jiang
et
al
yoshiohoshino
et
al
studi
use
ad
vector
ab
gene
deliveri
still
underrepres
treatment
infecti
diseas
kasuya
et
al
report
substanti
surviv
advantag
anthrax
lethal
toxin
achiev
ad
vectormedi
recab
gene
transfer
kasuya
et
al
recombin
ad
attract
deliveri
vehicl
applic
mani
reason
ad
vector
stabl
easili
engin
incorpor
larg
transgen
hightit
product
purif
easili
achiev
use
inexpens
method
extens
safeti
record
replicationdefici
recombin
ad
human
nih
report
transduct
effici
achiev
use
ad
vector
vivo
unparallel
among
gene
deliveri
vector
either
nonvir
viral
intrins
properti
replicationincompet
ad
vector
mediat
transient
gene
transfer
look
especi
attract
context
acut
infecti
diseas
treatment
recab
vector
clear
organ
diseas
elimin
howev
antibodi
molecul
product
two
gene
express
special
attent
given
design
gene
deliveri
vector
encod
recab
difficult
achiev
balanc
express
two
gene
singl
vector
singlechain
variabl
fragment
scfv
genet
engin
singl
polypeptid
molecul
consist
variabl
fragment
heavi
chain
vh
light
chain
vl
immunoglobulin
join
togeth
flexibl
peptid
linker
recab
engin
possess
new
use
properti
fusion
scfv
protein
includ
immunoglobulin
constant
fragment
therebi
introduc
new
therapeut
physiolog
andor
biochem
function
function
activ
success
therapeut
ab
like
dictat
entir
structur
composit
mean
antigen
ag
bind
effector
portion
recombin
antibodi
preserv
recent
lo
et
al
describ
approach
permit
high
level
product
recombin
protein
eukaryot
express
system
wherebi
protein
interest
produc
carboxytermin
fusion
protein
immunoglobulin
constant
fragment
fragment
crystalliz
fc
lo
et
al
swap
fc
portion
recab
possibl
tailor
effector
function
develop
approach
design
produc
recombin
antibodi
molecul
includ
scfv
ctermin
fusion
igg
fc
fragment
demonstr
recombin
antibodi
configur
retain
bind
properti
korokhov
et
al
current
studi
describ
admedi
gene
transfer
wnvneutral
recab
gene
result
high
sustain
level
protect
recab
vivo
demonstr
singl
inject
engin
ad
prevent
develop
lethal
wnv
infect
mice
wnv
strain
grown
vero
cell
atcc
c
humidifi
atmospher
contain
co
dulbecco
modifi
eagl
medium
dmem
supplement
fetalclon
iii
fciii
hyclon
logan
ut
antibioticantimycot
mixtur
invitrogen
carlsbad
ca
strain
lvov
et
al
obtain
state
collect
viru
strain
ivanovskii
institut
virolog
russian
academi
medic
scienc
strain
melnick
et
al
obtain
dr
l
zeng
cber
bethesda
md
isol
strain
tesh
et
al
provid
dr
r
tesh
galveston
tx
recombin
ad
vector
rescu
propag
cell
atcc
human
lung
adenocarcinoma
cell
atcc
use
vitro
product
antibodi
cell
grown
medium
supplement
fc
antibioticantimycot
mixtur
fragment
encod
ctermin
portion
envelop
e
protein
wnv
wnvec
aa
genbank
pcramplifi
construct
describ
razumov
et
al
clone
express
vector
novagen
madison
wi
protein
produc
de
plyss
bacteria
purifi
immobil
metal
affin
chromatographi
imac
use
talon
resin
clontech
paolo
alto
ca
follow
dialysi
pb
gener
scfv
total
rna
isol
hybridoma
cell
line
secret
neutral
monoclon
antibodi
mab
wnv
envelop
protein
use
rneasi
kit
qiagen
valencia
ca
monoclon
antibodi
produc
hybridoma
demonstr
high
neutral
activ
sever
wnv
isol
mab
recogn
ctermin
portion
wnv
e
protein
domain
iii
razumov
et
al
code
dna
synthes
use
omniscript
rt
kit
qiagen
valencia
ca
use
pcr
amplif
vh
vl
gene
fragment
set
publish
primer
breitl
et
al
pcr
product
ligat
phagemid
vector
breitl
et
al
escherichia
coli
cell
bear
infect
helper
phage
result
bacteriophag
display
scfv
variant
phagescfv
minilibrari
screen
use
purifi
wnvec
describ
kontermann
posit
phage
clone
identifi
elisa
use
purifi
wnvec
nucleotid
sequenc
scfv
determin
dna
sequenc
phage
replic
form
dna
scfv
gene
reclon
bacteri
express
vector
dubel
et
al
featur
cmyc
detect
tag
purif
tag
assembl
dna
perform
follow
hing
domain
collect
call
fc
fragment
crystalliz
human
immunoglobulin
gene
pcramplifi
cdna
clone
open
biosystem
huntsvil
al
genbank
introduc
singl
cy
ser
accord
amino
acid
substitut
hing
region
cystein
residu
normal
form
disulfid
bond
light
chain
fc
gene
fragment
clone
vector
invitrogen
frame
murin
ig
kappachain
signal
peptid
sequenc
gene
scfv
pcr
amplifi
clone
frame
leaderfc
gener
entir
express
cassett
includ
cmv
promot
bovin
growth
hormon
bgh
polyadenyl
signal
reclon
pshuttl
vector
stratagen
la
jolla
ca
gener
gener
recombin
ad
genom
adeasi
adenovir
vector
system
stratagen
use
accord
instruct
manual
recombin
ad
viru
genom
transfect
cell
recombin
viru
rescu
massproduc
follow
cscl
gradient
purif
biolog
viru
titer
determin
per
adeasi
manual
plaqueform
unit
pfu
cell
viru
particl
vp
titer
determin
spectrophotometr
maizel
et
al
use
convers
factor
vp
per
one
absorb
unit
nm
ad
vector
encod
irrelev
recab
recogn
spike
protein
sar
coronaviru
gener
similarli
vp
pfu
ratio
ad
prepar
use
studi
product
recombin
use
express
system
cell
transduc
multipl
infect
moi
vpcell
infect
carri
h
c
follow
medium
replac
medium
replac
everi
day
day
postinfect
collect
supernat
recombin
protein
purifi
use
protein
antibodi
purif
kit
sigma
st
loui
mo
protein
concentr
determin
bradford
protein
assay
biorad
hercul
ca
bovin
gamma
globulin
standard
test
product
cell
aliquot
purifi
recab
separ
gradient
sd
paag
sampl
run
either
boil
unboil
form
assay
dimer
format
also
omit
unboil
sampl
follow
western
blot
horseradish
peroxidas
hrp
label
goat
antihuman
igg
ab
dako
carpinteria
ca
diaminobenzidin
dab
sigma
stain
bind
wnv
virion
examin
indirect
elisa
captur
ab
anti
wnv
mab
razumov
et
al
irrelev
mab
neg
control
use
gwell
well
incub
wnvinfect
vero
cell
lysat
tripl
freezingthaw
follow
sonic
follow
dilut
bind
wnvec
test
elisa
wnvec
absorb
plastic
micropl
ngwell
aliquot
dilut
ad
well
follow
hrplabel
goat
antihuman
igg
ab
orthophenylen
diamin
opd
sigma
stain
interact
wnv
e
protein
also
examin
radioimmunoprecipit
rip
describ
previous
yamshchikov
et
al
briefli
bhk
cell
transfect
infecti
clone
yamshchikov
et
al
label
h
postinfect
ci
met
easytag
perkinelm
waltham
chase
h
complet
growth
medium
virusspecif
protein
immunoprecipit
cultur
medium
cell
lysat
use
either
wnv
e
proteinspecif
mab
oliph
et
al
purifi
proteina
agaros
protein
separ
use
sdspage
visual
use
xray
film
kodak
biomax
fisher
pittsburgh
pa
wnv
neutral
assay
perform
vero
cell
use
microplaqu
reduct
neutral
test
prnt
report
earlier
yamshchikov
et
al
yamshchikov
et
al
mice
maintain
accord
american
associ
accredit
laboratori
anim
care
guidelin
anim
protocol
review
approv
kansa
univers
institut
anim
care
use
committe
determin
circul
level
result
ad
inject
femal
balbc
mice
charl
river
laboratori
wilmington
week
age
inocul
intraperiton
ip
either
pfu
sera
sampl
collect
day
postinocul
kept
c
analysi
three
mice
per
time
point
sacrif
per
viral
dose
concentr
individu
sera
determin
use
human
igg
elisa
quantit
kit
bethyl
lab
montgomeri
tx
anim
protect
studi
femal
swiss
webster
outbr
mice
harlan
indianapoli
inocul
ip
either
encod
irrelev
recab
group
six
mice
inocul
correspond
recad
pfumous
h
ii
simultan
iii
h
ip
challeng
wnv
pfumous
control
group
six
mice
infect
pfu
mice
monitor
surviv
day
blood
sampl
collect
indic
time
point
test
circul
antiwnv
mous
igm
mous
antiwnv
igm
level
mous
sera
protect
studi
determin
elisa
use
semipurifi
viral
antigen
wnv
pellet
sucros
cushion
solubil
pb
describ
earlier
yamshchikov
et
al
yamshchikov
et
al
use
either
goat
antihuman
igg
goat
antimous
igm
hrplabel
secondari
antibodi
color
reaction
develop
tetramethylbenzidin
tmb
sigma
differ
surviv
mice
analyz
use
kaplanmei
method
group
compar
use
logrank
test
use
graphpad
prism
softwar
antibodi
titer
measur
challeng
experi
compar
repeat
measur
anova
analysi
naturallogarithm
ln
transform
valu
p
consid
signific
aim
studi
test
whether
genebas
vivo
product
pathogenspecif
neutral
recab
use
treatment
infecti
diseas
achiev
gener
recombin
ad
vector
encod
secret
recab
use
genet
materi
hybridoma
cell
line
secret
monoclon
antibodi
fig
mab
display
strong
neutral
activ
differ
strain
wnv
razumov
et
al
code
dna
vh
vl
portion
mab
pcramplifi
clone
encod
scfv
fig
fig
express
cassett
gener
includ
gene
secret
mous
ig
kappa
leader
peptid
follow
human
fc
scfv
orf
upstream
polyadenyl
signal
entir
cassett
control
cmv
promot
incorpor
ad
vector
result
recombin
viru
fig
use
studi
vitro
protein
product
vivo
recab
gene
deliveri
fig
anticip
inocul
anim
sustain
level
wnvneutral
recab
blood
confer
protect
otherwis
lethal
wnv
infect
sequenc
scfv
vh
vl
deposit
genbank
access
number
respect
fig
schemat
outlin
studi
genet
materi
form
hybridoma
secret
wnvneutral
mab
use
gener
scfv
b
c
code
sequenc
express
cassett
compris
orf
preced
mous
kappa
chain
leader
peptid
sequenc
follow
polyadenyl
signal
place
control
cmv
promot
introduc
ad
genom
use
gener
recombin
vector
use
inocul
mice
e
achiev
vivo
product
result
wnv
neutral
anim
protect
scfv
produc
bacteria
purifi
periplasm
extract
shown
recogn
purifi
ctermin
fragment
wnv
e
proteinwnvec
elisa
data
shown
produc
vitro
purifi
cultur
supernat
cell
use
protein
chromatographi
yield
admedi
recab
product
mgl
western
blot
purifi
stain
antihuman
igg
ab
fig
reveal
specif
band
kda
left
lane
correspond
recab
monomer
form
reduc
condit
c
unreduc
boil
migrat
kda
band
right
lane
correspond
dimer
form
recab
purifi
fig
character
western
blot
purifi
cell
transduc
recab
protein
apurifi
cultur
supernat
aliquot
purifi
recab
separ
sdspage
follow
western
blot
hrplabel
goat
antihuman
igg
ab
dab
stain
r
sampl
reduc
boil
condit
ur
sampl
unreduc
boil
condit
b
indirect
elisa
wnvinfect
cell
lysat
anti
wnv
mab
squar
irrelev
mab
diamond
use
captur
ab
well
incub
wnvinfect
vero
cell
lysat
follow
antihuman
igghrp
dab
stain
c
radioimmunoprecipit
lysat
bhk
cell
transfect
infecti
clone
cell
lysat
incub
lane
wnv
e
proteinspecif
mab
lane
follow
precipit
protein
agaros
protein
separ
sdspage
visual
xray
film
elisa
wnvec
incub
either
wnvec
squar
casein
diamond
follow
hrplabel
goat
antihuman
igg
ab
dab
stain
demonstr
specif
bind
wnv
virion
strain
indirect
elisa
fig
purifi
specif
immunoprecipit
wnv
e
protein
lysat
wnv
infect
radiolabel
bhk
cell
fig
shown
previous
razumov
et
al
mab
interact
ctermin
portion
wnv
e
protein
elisa
correspond
antigen
wnvec
demonstr
retain
specif
bind
antigen
fig
confirm
western
blot
purifi
wnvec
data
shown
next
examin
abil
purifi
neutral
wnv
vitro
use
plaqu
reductionneutr
test
shown
tabl
effici
neutral
infect
wnv
strain
isol
expect
also
neutral
wnv
strain
data
shown
thu
adenoviru
encod
recombin
antibodi
achiev
high
level
recab
product
cell
cultur
demonstr
form
dimer
retain
parent
mab
specif
ctermin
portion
wnv
e
protein
effici
neutral
differ
isol
wnv
anticip
inocul
anim
result
sustain
level
recab
circul
would
last
time
suffici
complet
abrog
wnv
infect
order
evalu
paramet
inject
mice
monitor
human
igg
fc
blood
week
inocul
two
group
mice
inject
ip
dose
pfu
per
mous
result
shown
fig
demonstr
dose
pfumous
recab
alreadi
detect
blood
h
postinocul
reach
maximum
level
day
postinocul
detect
recab
level
still
observ
even
day
postinocul
dose
pfumous
result
lower
overal
recab
level
earlier
decreas
beyond
detect
limit
ultim
goal
studi
demonstr
admedi
recab
gene
deliveri
result
sustain
circul
level
abrog
lethal
wnv
infect
anim
model
test
mice
infect
pfu
wnv
ld
yamshchikov
et
al
treat
encod
irrelev
recab
day
prevent
studi
therapeut
studi
regard
challeng
shown
fig
admedi
vivo
product
anti
wnv
result
remark
increas
surviv
anim
compar
receiv
ad
encod
irrelev
recab
fig
surviv
fig
mediat
protect
wnv
encod
irrelev
recab
b
inocul
ip
pfumous
h
squar
simultan
triangl
h
circl
ip
challeng
wnv
swiss
webster
mice
use
mice
per
group
one
group
diamond
use
control
viral
infect
mice
monitor
surviv
day
anim
achiev
administ
h
wnv
challeng
surviv
advantag
group
group
receiv
ad
vector
statist
signific
p
logrank
test
mice
surviv
ad
vector
given
either
simultan
h
challeng
surviv
group
significantli
higher
control
group
p
logrank
test
serum
level
wnv
challeng
determin
elisa
use
coat
antigen
expect
clearli
detect
monitor
interv
fig
indic
establish
progress
activ
wnv
infect
product
host
igm
earli
stage
process
tardei
et
al
measur
mous
antiwnv
igm
blood
cours
treatment
shown
fig
level
wnvspecif
igm
rise
anim
receiv
thu
indic
effici
suppress
infect
contrast
mice
receiv
control
ad
show
significantli
higher
host
igm
level
anim
receiv
ad
h
p
time
challeng
p
statist
signific
differ
observ
mice
group
receiv
ad
h
challeng
like
indic
establish
initi
wnv
infect
later
abrog
recab
gene
transfer
result
increas
surviv
comparison
made
day
postwnv
challeng
use
antibodybas
therapi
infecti
agent
routin
clinic
practic
although
effici
mani
applic
limit
sever
factor
includ
safeti
issu
cost
therapeut
antibodi
among
expens
drug
use
clinic
practic
kasuya
et
al
high
cost
ig
prepar
relat
fact
reagent
requir
special
handl
costli
obtain
produc
maintain
immunoglobulin
deriv
immun
donor
may
contain
adventiti
agent
includ
yet
unknown
one
may
potenti
biohazard
otherwis
sinc
puriti
achiev
addit
vitro
product
ab
especi
full
size
twochain
ab
requir
tediou
optim
yield
often
low
show
studi
altern
purifi
ab
prepar
passiv
immun
genebas
deliveri
protect
recab
offer
number
advantag
first
recab
produc
vivo
therefor
properli
process
host
mechan
second
need
recab
purif
although
clinic
vector
prepar
produc
accord
accept
criteria
third
recab
gene
express
maintain
time
thu
elimin
need
repeat
inject
ab
maintain
therapeut
concentr
import
safeti
featur
propos
treatment
use
replic
incompet
ad
vector
recab
gene
deliveri
abil
replicationdefici
ad
vector
mediat
transient
gene
transfer
look
especi
attract
context
acut
infecti
diseas
treatment
recab
strategi
describ
highli
generaliz
swap
pathogen
bindingneutr
portion
recab
possibl
gener
therapeut
infecti
agent
passiv
immun
proven
effect
approach
use
atrisk
individu
laboratori
personnel
possibl
bioterror
attack
preexist
anti
ad
immun
result
previou
exposur
ad
either
natur
infect
administr
vector
may
affect
applic
longterm
express
necessari
requir
readministr
vector
follow
eventu
loss
therapeut
transgen
express
show
singl
dose
adrecab
treatment
abrog
wnv
infect
laboratori
anim
nevertheless
need
repeat
ad
administr
aris
sever
studi
document
effect
readministr
certain
applic
exampl
phase
iii
trial
recurr
ovarian
cancer
intraperiton
readministr
use
transgen
express
measur
sampl
obtain
two
three
cycl
buller
et
al
anoth
phase
clinic
test
patient
sera
posit
anti
ad
antibodi
result
reduct
transgen
express
ip
administr
encod
intrabodi
alvarez
et
al
thu
recogn
abil
effect
repeat
administ
ad
vector
dosedepend
sitespecif
present
studi
describ
gener
recab
compris
fusion
protein
fc
portion
human
link
scfv
deriv
hybridoma
secret
mab
capabl
neutral
differ
isol
wnv
mab
shown
previous
recogn
ctermin
portion
domain
iii
wnv
e
protein
razumov
et
al
domain
iii
put
receptor
bind
domain
viru
crill
roehrig
import
target
neutral
antibodi
beasley
barrett
oliph
et
al
razumov
et
al
sanchez
et
al
neutral
ab
bind
e
protein
prevent
infect
cell
block
attach
viru
cellular
receptor
attach
factor
crill
roehrig
recent
data
suggest
diiispecif
neutral
antibodi
may
also
inhibit
postattach
step
replicationdefici
recombin
ad
vector
gener
encod
control
power
cmv
promot
recombin
ad
mediat
sustain
level
recab
product
system
administr
mice
last
least
week
postinocul
expect
genebas
vivo
express
recab
may
serv
effici
treatment
acut
infecti
process
confirm
wnv
challeng
studi
mice
treat
experi
perform
use
three
regimen
ad
vector
given
day
lethal
wnv
challeng
ii
ad
vector
given
simultan
lethal
wnv
challeng
iii
ad
vector
given
day
lethal
wnv
challeng
outstand
anim
protect
observ
singl
inject
three
treatment
group
contrast
high
mortal
control
group
receiv
encod
irrelev
recab
mice
surviv
group
receiv
ad
encod
wnvspecif
recab
simultan
h
lethal
wnv
challeng
treatment
wnv
challeng
anim
result
signific
sustain
specif
recab
level
sera
inocul
mice
determin
wnvspecif
elisa
sinc
wnvspecif
igm
respons
detect
anim
conclud
treatment
effect
suppress
develop
activ
wnv
infect
thu
singl
dose
recombin
ad
vector
mediat
wnvspecif
recab
gene
deliveri
result
abrog
acut
wnv
infect
prophylact
therapeut
treatment
regiment
knowledg
first
demonstr
ad
mediat
recab
gene
transfer
result
abrog
acut
infecti
process
ablat
infect
support
observ
suppress
earli
igm
respons
anim
surviv
lethal
challeng
earlier
kasuya
et
al
demonstr
ad
mediat
vivo
neutral
anthrax
toxin
kasuya
et
al
infect
caus
activ
pathogen
time
passiv
ab
administr
rel
develop
clinic
symptom
determin
factor
treatment
efficaci
elimin
wnv
diseas
shown
success
preexist
ab
administ
even
day
viru
challeng
demonstr
recab
deliv
day
challeng
abrog
wnv
infect
determin
admedi
efficaci
later
wnv
infect
stage
subject
ongo
studi
besid
direct
pathogen
neutral
vivo
protect
antibodi
even
nonneutr
vitro
util
mechan
elimin
pathogen
abrog
diseas
eg
antibodydepend
complementmedi
cellular
cytotoxicityfunct
attribut
fc
key
event
former
mechan
interact
igg
attach
infect
cell
receptor
iii
residu
leuleuglyglypro
lower
hing
implic
receptor
bind
lund
et
al
sinc
preserv
function
present
describ
construct
residu
respons
complement
subcompon
bind
igg
idusogi
et
al
also
preserv
construct
therefor
latter
function
neonat
fc
receptor
fcrn
play
import
role
regul
igg
circul
halflif
favor
recycl
andor
transcytosi
rather
catabol
gheti
ward
residu
respons
fc
interact
fcrn
identifi
domain
kim
et
al
well
preserv
construct
experiment
confirm
import
effector
function
inde
retain
construct
plan
detail
studi
mechan
antiwnv
protect
